NZ765637A - Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome - Google Patents

Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome

Info

Publication number
NZ765637A
NZ765637A NZ765637A NZ76563718A NZ765637A NZ 765637 A NZ765637 A NZ 765637A NZ 765637 A NZ765637 A NZ 765637A NZ 76563718 A NZ76563718 A NZ 76563718A NZ 765637 A NZ765637 A NZ 765637A
Authority
NZ
New Zealand
Prior art keywords
female subject
subject suffering
inositol
polycystic ovary
embryo implantation
Prior art date
Application number
NZ765637A
Other languages
English (en)
Inventor
Martín Mónica Olivares
Joyá Juristo Fonollá
Medina María Paz Díaz-Ropero
Larramendi José Luis López
Ladrón De Guevara Nicolás Mendoza
Original Assignee
Biosearch S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosearch S A filed Critical Biosearch S A
Publication of NZ765637A publication Critical patent/NZ765637A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ765637A 2017-11-23 2018-04-19 Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome NZ765637A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382791 2017-11-23
PCT/EP2018/060077 WO2019101368A1 (en) 2017-11-23 2018-04-19 Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
NZ765637A true NZ765637A (en) 2025-11-28

Family

ID=60569854

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ765637A NZ765637A (en) 2017-11-23 2018-04-19 Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome

Country Status (12)

Country Link
US (1) US11484540B2 (https=)
EP (1) EP3713552A1 (https=)
JP (1) JP7257399B2 (https=)
CN (1) CN111655245B (https=)
AU (1) AU2018373174B2 (https=)
BR (1) BR112020010343A2 (https=)
CA (1) CA3083301C (https=)
MA (1) MA50784A (https=)
MX (1) MX2020005223A (https=)
NZ (1) NZ765637A (https=)
TW (1) TWI842684B (https=)
WO (1) WO2019101368A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749783C1 (ru) * 2020-12-11 2021-06-16 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения синдрома поликистозных яичников, ассоциированного с метаболическим синдромом
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
EP4620480A1 (en) 2022-11-16 2025-09-24 Kansai Medical University Educational Corporation Implantation facilitator, and screening system therefor
CN117017929B (zh) * 2023-09-11 2024-11-08 山东奥克斯畜牧种业有限公司 一种用于提高采卵效果的组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047686C (en) 1989-03-08 2000-09-05 Joseph Larner Dietary supplement for insulin-resistant diabetics
US5563059A (en) 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
JP2006213684A (ja) 2005-02-07 2006-08-17 Hokko Chem Ind Co Ltd インスリン抵抗性改善に用いられる組成物及び健康用食品
ITRM20070341A1 (it) * 2007-06-20 2008-12-21 Lo Li Pharma Srl Formulazione integrativa inofolic finalizzata al controllo dell'induzione dell'ovulazione in programmi di procreazione medicalmente assistita
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
ITFI20110252A1 (it) * 2011-11-22 2013-05-23 Lo Li Pharma Srl Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo.
ITRM20130655A1 (it) * 2013-11-26 2015-05-27 Dicofarm Spa Prodotto a base di una associazione di glucomannano ed inositolo
US9259410B2 (en) 2014-04-08 2016-02-16 Oculus Innovative Sciences, Inc. Methods of treating polycystic ovarian syndrome using chlorogenic acid and inositol
IN2014MU01312A (https=) 2014-04-09 2015-10-16 Olive Healthcare
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico

Also Published As

Publication number Publication date
JP7257399B2 (ja) 2023-04-13
MX2020005223A (es) 2020-10-19
EP3713552A1 (en) 2020-09-30
MA50784A (fr) 2020-09-30
BR112020010343A2 (pt) 2020-11-10
TWI842684B (zh) 2024-05-21
CN111655245A (zh) 2020-09-11
CA3083301A1 (en) 2019-05-31
US11484540B2 (en) 2022-11-01
JP2021504360A (ja) 2021-02-15
RU2020120655A3 (https=) 2021-12-23
TW201924692A (zh) 2019-07-01
AU2018373174A1 (en) 2020-07-09
US20200330495A1 (en) 2020-10-22
CA3083301C (en) 2024-05-21
WO2019101368A1 (en) 2019-05-31
CN111655245B (zh) 2023-08-08
RU2020120655A (ru) 2021-12-23
AU2018373174B2 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
NZ765637A (en) Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome
MX386086B (es) Composicion de cannabis
MX2019014974A (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2016137164A3 (ko) 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
NZ738597A (en) Stuffy nose deblocking composition having antiviral activity
EP4483890A3 (en) Vitamin b2 and myo-inositol for treating and preventing gestational diabetes
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
GEAP202215306A (en) Formulations of copanlisib
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
NZ710583A (en) Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
WO2019022482A3 (ko) 황칠나무 추출물을 유효성분으로 포함하는 섬유화 질환의 예방 또는 치료용 조성물
ZA202107346B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
PH12020550104A1 (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
TN2018000355A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain.
NZ735025A (en) Use of fenugreek extract to enhance psychological, somatic, and sexual conditions in aging males
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
EA201991269A1 (ru) Профилактический агент, агент, подавляющий начало заболевания, или терапевтический агент для прогрессирующих иммунных демиелинизирующих заболеваний
TN2018000091A1 (en) Oxa-diazaspiro compounds having activity against pain

Legal Events

Date Code Title Description
PSEA Patent sealed